Abstract
Objectives: Biologic drugs used in treatment of rheumatoid arthritis (RA) increase economic burden of RA on health care systems. Thus, pharmacoeconomic (PE) studies of treatment options in RA are valuable for decision-makers in the health care sector. Previous literature has demonstrated the presence of wide variations in PE study outcomes
... read more